APIs pour la recherche et les impuretés

NLRP3i is a molecule that is orally administered and has been shown to have anti-inflammatory effects in the heart. NLRP3i reduces pro-inflammatory cytokines and protects against cardiac dysfunction in mice with chronic kidney disease. It also protects against heart failure caused by ischemia reperfusion. This drug has been shown to be effective as a therapy for cancer, with some patients being resistant to chemotherapy, although it is not yet approved for this use.

Tacrolimus is a macrolide that is used as an immunosuppressive drug. It has been shown to bind to the FK-binding protein, which in turn inhibits calcineurin. This prevents the release of IL-2, TNF-α and other cytokines. The immunosuppressive effects of tacrolimus have been evaluated using analytical methods such as coefficients, affinity, and monitoring techniques such as immunoassays and agglutination. These techniques are used to evaluate the plasma concentration of tacrolimus. Tacrolimus also binds to proteins in the blood samples and can be detected by turbidimetric or electrochemiluminescence immunoassay reagents.

Please enquire for more information about (3R)-3-Amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-α]pyrazin-7(8H)-yl]-4-(2,3,6-trifluorophenyl)-1-butanone including the price, delivery time and more detailed product information at the technical inquiry form on this page

Memantine impurity IV is a hydrolysis product of memantine. It appears as a white to off-white powder and has a molecular weight of 198.1 g/mol. Memantine impurity IV is an intermediate in the production of memantine and is therefore not used for any other purpose. The compound contains hydroxy groups, hydroxy, alcohols, and bridgehead groups which are efficient at hydrolyzing to form amino acids.

Dicyclopropylamine is a molecule that has been clinically developed as a drug. It is an inhibitor of the enzyme tyrosinase, which is involved in the production of melanin, and has been shown to have anti-cancer properties. Dicyclopropylamine hydrochloride has been shown to be effective against aliphatic hydrocarbons such as hexane and cyclohexane, as well as aromatic compounds such as benzene and toluene. This drug can also bind to coordination complexes with high kinetic energy, which may be useful for tumor treatment. Dicyclopropylamine hydrochloride can be used for the clinical treatment of human epidermoid carcinoma.

11-Fluoro desloratadine is a metabolite of the antihistamine, loratadine. It has shown to be an analytical standard for HPLC, and impurity standard for pharmacopoeia. 11-Fluoro desloratadine is typically synthesized by reacting loratadine with fluorinating reagent such as N-fluorosuccinimide (NFSI) in the presence of a base catalyst such as sodium methoxide. 11-Fluoro desloratadine is also found in breast milk at concentrations of up to 1.2% of total loratadine concentration, which has been attributed to incomplete metabolism or passive transfer from mother to child.

Cetirizine is a drug product that is metabolized to cetirizine propanediol ester. This impurity has been identified in the drug and is not expected to cause any adverse effects in humans. Cetirizine propanediol ester can be synthesized and purified through high-purity, analytical, and natural methods. The pharmacopoeia defines cetirizine propanediol ester as a metabolite of cetirizine. It can also be used as an impurity standard for HPLC analysis.

Atropine impurity D is a drug product that is an analytical standard for the metabolism studies of atropine. It is a natural API that belongs to the group of drugs and has CAS number 72-48-0. This drug has been synthesized from the synthetic process and then purified by HPLC. The purity of this drug exceeds 99%. Atropine impurity D is used as an impurity standard in pharmacopoeia, research and development, and drug development.

Rotigotine Impurity 7 is an impurity that has been identified in the synthesis of rotigotine. Rotigotine Impurity 7 is a synthetic compound with a CAS number of 1229620-82-9. It is intended for use as an analytical standard and as a component in the manufacture of rotigotine, which is indicated for the management of Parkinson's disease. This product has not been tested in animals or humans, and it should be handled with care.

Terbutaline Impurity D is a synthetic drug with the CAS number 94109-61-2. This product has been developed as an impurity standard for Terbutaline, which is a drug product that has been approved by the United States Pharmacopoeia (USP). Terbutaline Impurity D can be used to study the metabolism of Terbutaline in animals. It is also used to develop new drugs by chemists and other scientists.

(R)-(+)-1,1,2-Triphenyl-1,2-ethanediol is a heterocyclic compound with a five-membered ring. It is chiral and has two stereogenic centers in its structure. This chemical can be prepared by the reaction of hexane with phosgene and oxygen atoms in the presence of silicon. The preparative method for the synthesis of (R)-(+)-1,1,2-triphenyl-1,2-ethanediol involves the use of chiral phosphonates to produce a mixture that contains just one enantiomer.

Esomeprazole Impurity Q is a drug product. It is an impurity standard of esomeprazole, CAS No. 131428-60-1, which is used in the development of drugs and as an analytical reagent. It is synthesized from natural materials and has a purity of 99%. The metabolite can be found in animal and human metabolism studies. Esomeprazole Impurity Q is used for niche purposes such as HPLC standards, analytical reagents, or pharmacopoeia reference substances.

CPI 0610 is a medicinal compound that acts as a potent inhibitor of protein phosphorylation. It has been shown to inhibit the cell cycle and promote apoptosis in Chinese hamster ovary cells. CPI 0610 is an effective inhibitor of kinase activity in cancer cells, leading to decreased tumor growth and increased survival rates. In preclinical studies, CPI 0610 has demonstrated efficacy against a wide range of cancers, including breast, prostate, and lung cancer. This inhibitor has also been shown to be effective in human cancer cell lines, making it a promising candidate for future cancer therapies.

2-(4-Formylphenyl)propionic acid is a racemic mixture of 2-formylphenylacetic acid and 4-formylphenylacetic acid. This compound is used in the treatment of bacterial infections and inflammation. It is an organic solution that can be injected, administered orally, or applied topically. The 2-(4-formylphenyl)propionic acid has been shown to have anti-inflammatory properties, but also has side effects such as skin irritation when it is applied topically. This drug can also cause nausea, vomiting, and diarrhea when administered orally.

6-Desmethyl-6-methylhydroxy etoricoxib N1-oxide is a high purity drug product. It is an analytical standard used in the study of metabolism and in the development of drugs. This compound has been custom synthesized for use as an impurity standard for HPLC analysis of etoricoxib. 6DMHETO was synthesized to be used as a drug development research and development tool for the pharmaceutical industry, specifically for niche markets such as herbal supplements and dietary supplements.

Erlotinib-3-vinyl hydrochloride is a drug product that is used in the treatment of cancer, including non-small cell lung cancer. It is an impurity standard for HPLC and analytical testing. Erlotinib-3-vinyl hydrochloride is also used as an API impurity and metabolite in metabolism studies. Erlotinib-3-vinyl hydrochloride can be synthesized from 4-(4'-vinylphenoxy)butanal, which is a natural compound obtained from plants like apple trees. This synthetic process can be done by the reduction of 4-(4'-vinylphenoxy)butanal with sodium borohydride, followed by reaction with vinyl chloride. The compound is also found as a metabolite in humans after oral administration of erlotinib, which has been shown to inhibit protein synthesis and DNA synthesis.